Review Article
TGF-β signaling and its targeting for glioma treatment

Jianfeng Han\textsuperscript{1,2}, Christopher A Alvarez-Breckenridge\textsuperscript{3}, Qi-En Wang\textsuperscript{2}, Jianhua Yu\textsuperscript{1,2}

\textsuperscript{1}Division of Hematology, Department of Internal Medicine, College of Medicine, The Ohio State University, Columbus, Ohio 43210, USA; \textsuperscript{2}The Ohio State University Comprehensive Cancer Center, Columbus, Ohio 43210, USA; \textsuperscript{3}Department of Neurosurgery, Massachusetts General Hospital, Boston, Massachusetts 02114, USA

Received February 7, 2015; Accepted February 19, 2015; Epub February 15, 2015; Published March 1, 2015

Abstract: Transforming growth factor-beta (TGF-β) is a pleiotropic cytokine, secreted by a variety of cells including immune cells, tumor cells, and stromal cells. TGF-β signaling is dysregulated in cancer patients, and this aberrant signaling at least in part contributes to initiation and progression of many cancers including glioma. The dysregulated signaling components provide molecular targets for the treatment of glioma. In this article, we review TGF-β signaling and its targeting in glioma.

Keywords: TGF-β, TGF-β signaling, glioma, gliomagenesis, glioma treatment

Introduction
Transforming growth factor-beta (TGF-β) is a multifunctional cytokine that regulates cell proliferation, differentiation and tissue homeostasis [1]. The TGF-β superfamily includes various TGF-βs (TGF-β1, -β2, and -β3, which are highly homologous), Activin, Nodal, growth and differentiation factors (GDFs), bone morphogenetic proteins (BMPs), and anti-mullerian hormone (AMH) [2].

In the latent form, TGF-β binds with latent TGF-β binding protein (LTBP) and latency-associated peptide (LAP) to form a latent complex [3]. Many kinds of proteases such as plasmin can catalyze the latent complex of TGF-β to release the active TGF-β. Active TGF-β signals via a heteromeric complex of type I and type II transmembrane serine/threonine kinase receptors and activates different intracellular signaling pathways. TGF-β first binds to TGF-β receptor II (TGFβRII) and alters its conformation, and then TGFβRII phosphorylates TGF-β receptor I (TGFβRI, also termed activin receptor-like kinase (ALK) 5) (Figure 1). Subsequently, TGFβRI phosphorylates receptor-regulated (R- ) Smad proteins (Smad 2, 3) on the C-terminal Ser-Ser-X-Ser motif. Activated R-Smads form heteromeric complexes with the Co-Smad, Smad-4, and translocate to the nucleus (Figure 1), where they cooperate with other transcriptional regulators to regulate the expression of target genes such as plasminogen activator inhibitor-1, fibronectin, and collagen type I [4]. Smads consist of conserved Mad homology 1 (MH1), intermediate linker (L) and MH2 domains [5]. In most cell types, TGF-β transduces signals through TGFβRI. However, in endothelial cells, TGF-β signals through two distinct type I receptors, TGFβRI and ALK1, which lead to phosphorylation of Smad2/3 and Smad1/5, respectively [6]. Besides Smad-dependent pathways, various Smad-independent pathways have been identified, including MAPK, PI3K/Akt, JNK/p38, and Rho-like GTPase signaling in a cell type-specific and context-dependent manner [7].

In normal epithelial cells, TGF-β acts as a strong tumor suppressor at least in part due to its inhibitory effect on cell proliferation. This is at least in part attributed to TGF-β mediated pSmad3C (C-terminally phosphorylated Smad3) signaling that results in resistance to proliferative responses induced by mitogenic signals [8]. Even in premalignant stages of cancer, TGF-β can still act as a tumor suppressor by inhibiting epithelial cell proliferation and inducing apoptosis. However, during malignant transformation, epithelial cells or lymphoid cells, which constitute the basis of the majority of cancers in humans, become resistant to the growth inhibi-
TGF-β signaling and glioma treatment

Gliomas represent 80% of primary malignant brain tumors [14]. Gliomas are categorized into four grades according to the 2007 World Health Organization (WHO) classification criteria: grade I, grade II, grade III (anaplastic) and grade IV (glioblastoma, GB). GB is the most devastating malignant form of primary brain tumors and is

Figure 1. TGF-β signaling in gliomagenesis and its targeting. The TGF-β/Smads signaling pathway contributes to glioma development through induction of multiple carcinogenic processes. This pathway promotes glioma proliferation via PDGF-B and miR-182, invasiveness via miR-182, miR-10 and MMP, as well as angiogenesis via VEGF, IGFBP7, and JNK. The TGF-β/Smads signaling pathway induces immunosuppression by inhibiting NK cells, cytotoxic T lymphocytes (CTL), dendritic cells (DC), and by upregulating T regulatory (Treg) cells. The TGF-β/Smads signaling pathway also drives GSC stemness via LIF, Sox4-Sox2, and Id1-Id3. Aberant TGF-β signaling can be targeted by multiple approaches, including blockade of TGF-β mRNA translation using antisense oligonucleotides (AON) (AP12009), sequestering TGF-β with soluble receptors (sTGFβRII) or neutralizing antibodies (GC1008), and suppressing TGF-β receptors activity with kinase inhibitors (LY2157299, LY2109761 and SB-431542).
TGF-β signaling and its targeting for glioma treatment

characterized by high invasiveness, aberrant proliferation, chemo- and radiation therapy resistance, and relapse after surgical resection with a median overall survival of 14.6 months [15-17]. Given this poor prognosis, it is critical to understand the fundamental molecular pathways leading to glioma formation in order to develop novel therapeutic strategies for this disease. The TGF-β pathway has been identified as a mediator in glioma initiation and progression due to its effects on cell proliferation [18], tumor invasion [19], angiogenesis [20], immunosuppression [21] and the maintenance of stemness of glioma stem cells (GSCs) [22]. Additionally, human studies have demonstrated that TGF-β is overexpressed in malignant glioma tissues but undetectable in normal brain tissues, further suggesting that TGF-β contributes to glioma development. In particular, TGF-β2 is strongly upregulated in GB [23-25]. Here, we will write a review on the tumor promoting role of the TGF-β signaling pathway and the potential to target its signaling components for the treatment of GB.

TGF-β signaling in glioma cell proliferation

In most normal cells, TGF-βs act as the cell growth inhibitor. This cytostatic effect is dependent on its repression of c-myc and Id1-Id3 as well as its activation of cyclin-dependent kinase inhibitors p21WAF1/CIP1 and p15INK4B [18, 26]. In contrast, aberrant signaling in GB cells, such as alterations to the Smad, PI3K and FoxG1 signaling pathways mediate resistance to TGF-β-induced cell growth inhibition [26]. In addition, in GB cells, it is demonstrated that high TGF-β/Smad signaling induces induction of platelet derived growth factor-B (PDGF-B), thus resulting in tumor cell proliferation (Figure 1) [27]. In contrast, in gliomas that are not aggressive with a low proliferation index, TGF-β/Smad signaling is inactive and the induction of PDGF-B by TGF-β is impaired as the PDGF-B promoter remains hypermethylated [27].

TGF-β signaling in glioma invasion and migration

TGF-β is a key player in tumor invasion and metastasis [2]. Macrophages/microglia that constitute the major tumor-infiltrating immune cells in GB are recruited by tumor-secreted cytokines such as TGF-β1 and are induced to become immunosuppressive and adopt a tumor supportive/immune-suppressive phenotype (M2) [28]. TGF-β1 produced by glioma-infiltrating microglia/macrophages itself further enhances glioma invasion in vitro and in vivo [19]. TGFβRII downregulation with small hairpin RNAs (shRNAs) impairs TGF-β-induced GB invasiveness and migration in vitro in human T98G glioblastoma and rat C6 glioma cells. Moreover, C6 glioma cells stably expressing TGFβRII shRNAs in nude mice exhibit 50% less tumorigenicity. Microglia enhance glioma invasiveness when co-cultured with unmodified glioma cells, but this capability is lost when co-cultured with glioma cells stably expressing TGFβRII shRNA [19]. The invasiveness of GSCs is also crucial for the migration of glioma. In a recent study, glioma-associated macrophages/microglia with high expression of TGF-β1 could recruit CD133(+) GSCs. Furthermore, neutralization of TGF-β1 or knockdown of TGFβRII in GSCs inhibits their invasiveness [29]. Proteases such as the matrix metalloproteinases (MMPs) and cathepsins degrade the extracellular matrix, facilitating tumor cells to spread and invade [20, 29]. TGF-β is able to enhance MMPs expression and suppress tissue inhibitors of metalloproteinase (TIMP) (Figure 1), thus promoting invasiveness of U87 and LN-229 in matrigel invasion assays [30]. Additionally, TGF-β has been demonstrated to induce miR-10a/10b expression, which enhances glioma cell migration through suppression of PTEN (Figure 1) [31].

Radiation is considered an effective way to prolong survival of GB patients; however, tumor progression with enhanced invasiveness frequently occurs at or close to the original radiation treatment site [32]. Previous studies have demonstrated that irradiation increases the tumor cell invasion in malignant gliomas, but the mechanisms underlying this process are largely unknown. A study shows that, after irradiation, it is observed that both TGF-β and β1-integrin are increased and the invasion capability of U87 cells is enhanced in matrigel invasion assays [33], suggesting that increased TGF-beta may be associated with enhanced invasiveness of GB cells after irradiation.

Recently, TGF-β was also found to induce the expression of miR-182, a microRNA that directly suppresses cylindromatosis (CYLD). CYLD negatively regulates NF-κB activity by ubiquitin
TGF-β signaling and its targeting for glioma treatment

deconjugation. TGF-β-mediated suppression of CYLD leads to NF-κB activation, thus promoting glioma invasion and increasing its aggressiveness (Figure 1) [34].

TGF-β and angiogenesis

The growth of solid tumors including glioma requires neovascularization for nutrient delivery and debris management [35, 36]. The correlation between TGF-β and angiogenesis was reported in Chinese hamster ovary (CHO) cells which overexpress recombinant TGF-β1 [20]. After the subcutaneous injection of the modified CHO cells into nude mice, enhanced tumor proliferation and angiogenesis were observed compared to parental CHO cells. Treatment with TGF-β1 neutralizing antibody inhibited tumor growth and angiogenesis, confirming the role of TGF-β1 in angiogenesis [20]. TGF-β, especially TGF-β1, mediates this effect by up-regulation and activation of various angiogenic factors including vascular endothelial growth factor (VEGF), fibroblast growth factor (FGF) and plasminogen activator inhibitor (PAI-1) [35]. A transcriptional profiling study in human GB vessels further suggested that VEGF-A and TGF-β2 played key roles in GB angiogenesis [37]. Some studies have demonstrated that TGF-β signaling pathways and hypoxia synergize in VEGF gene regulation at the transcriptional level (Figure 1). Consistent with this observation, the human VEGF gene promoter region at -1006 to -954 is demonstrated containing functional DNA binding sites for both Smads and HIF-1 (hypoxia-inducible factor) [38].

In a zebrafish glioma model study, glioma U87 cells expressing red fluorescent protein (RFP) were transplanted in green fluorescent protein (GFP) transgenic zebrafish embryos as a model for studying angiogenesis [39]. TGF-β1 increased glioma-induced angiogenesis; however, this was abrogated by the c-Jun N-terminal kinase (JNK) inhibitor SP600125 but not by the ERK inhibitor PD98059, PI3K inhibitor LY294002, or p38 MAPK inhibitor SB202190. These findings demonstrated the critical role of TGF-β1 and JNK pathways in mediating angiogenesis (Figure 1) [39].

Insulin-like growth factor-binding protein 7 (IGFBP7) is highly expressed in tumor endothelial cells and vascular basement membrane, which makes it a biomarker of tumor vessels in GB [40]. Human brain endothelial cells (HBECs) treated with U87-conditioned media (CM) up-regulated IGFBP7 mRNA and protein in comparison to untreated HBECs [40]. ELISA assay showed that U87-CM contained sufficient TGF-β1 (5 pM) to stimulate IGFBP7 in HBEC. U87-CM-induced IGFBP7 expression in HBECs can be blocked by both TGFβR1 antagonist SB431542 and pan-TGF-β neutralizing antibody (1D11), indicating that TGF-β1 may be able to induce IGFBP7-dependent angiogenesis in brain endothelial cells (Figure 1) [40].

TGF-β signaling in tumor-mediated immunosuppression

Gliomas mediate an immunosuppressive tumor microenvironment through a variety of mechanisms (Figure 1). The immunosuppressive cytokines such as interleukin (IL)-10, TGF-β2, cyclooxygenase-2 (COX2) and prostaglandin E2 (PGE2) secreted by gliomas have been proven to play a major role in impeding anti-tumor immune responses in the microenvironment [41]. TGF-β2 down-regulates HLA-DR antigen expression on human malignant glioma cells, facilitating their immune escape from T lymphocytes [42]. Moreover, TGF-β has been reported to specifically inhibit the expression of perforin, granzyme A, granzyme B, IFN-γ, and Fas ligand, which are co-responsible for cytotoxic T lymphocyte (CTL)-mediated tumor cytotoxicity [43]. TGF-β also promotes the generation of immunosuppressive regulatory T (Treg) cells (Figure 1) [44] and TGF-β1 increases macrophage capacity to produce immunosuppressive cytokine IL-10 [45]. Furthermore, TGF-β1 suppresses the activating receptor NKG2D on the surface of CD8+ T cells and NK cells in glioma patients, rendering them less effective at cytotoxicity against glioma cells [46]. TGF-β is upregulated during malignant glioma progression, and this correlates with MICA (NKG2D ligand) downregulation. Consequently, NKG2D ligand-dependent NK cell-mediated lysis is decreased [47]. NKG2D down-regulation is prevented on the NK cell line, NKL, when incubated with supernatant from LN-229 glioma cells with TGF-β1/β2 knock-down by siRNA compared with supernatant from control LN-229 cells [48]. The TGF-β1/β2 knock-down in LN-229 cells also strongly up-regulates expression of MICA and renders the tumor cells more susceptible to killing by NK cells. LN-229 gli-
ma cells deficient in TGF-β show less subcutaneous and orthotopic tumorigenicity after implantation in nude mice, and isolated NK cells from these mice show an activated phenotype [48]. Additionally, TGF-β inhibits NK cell activity through Smad2, Smad3, and Smad4 (Figure 1) to suppress IFN-γ production by NK cells at least in part through inhibition of T-BET, a positive regulator of human NK cell function [49]. Additional work demonstrates that TGF-β/Smad signaling inhibits CD16-mediated human NK cell IFN-γ production and ADCC [50]. These negative modulations of T or NK cell activity by TGF-β in the tumor microenvironment are likely to be important for the immunosuppression observed in glioma patients, as T and NK cells have been identified as important immune cells for eradicating glioma cells [51-53].

There are a variety of antibodies and targeted inhibitors of TGF-β that aim to subvert TGF-β-mediated immunosuppression. Examples including the TGFβR1 kinase inhibitor SD-208 and the anti-TGF-β neutralizing monoclonal antibody (1D11) have been reported useful for enhancing the tumor-directed immune response and improving the therapeutic efficacy in the treatment of gliomas [36, 54]. Together, these findings demonstrate that immunotherapeutic strategies to suppress TGF-β signaling may be promising for improving the prognosis of patients with malignant gliomas.

**TGF-β and glioma-initiating cells**

Cancer stem cells or tumor-initiating cells are a subpopulation of tumor cells with the capability to undergo self-renewal and multi-lineage differentiation and to recapitulate the entire tumor population [55]. Autocrine TGF-β signaling has been shown to play an essential role in the maintenance of tumorigenicity of glioma stem cells (GSC) [22]. It has been demonstrated that human GSC express higher amounts of TGF-β2 than differentiated glioma cells, and the secreted TGF-β2 appears to correlate with the pathological grade of the glioma [56]. TGF-β produced by GSC enhances effective DNA damage response and self-renewal capacity, leading to microenvironment-mediated resistance to ionizing radiation (IR), while these effects are reversed by TGF-β inhibition through LY364947 (TGFβR1 kinase inhibitor) [57]. The Sox family of proteins have been demonstrated to maintain the GSC population. TGF-β is implicated in this pathway by directly inducing expression of Sox4, which promotes Sox2 expression by associating with the Sox2 enhancer region (Figure 1). Sox2 is an essential factor for maintenance of GSC stemness [22]. Sox2 knockdown by siRNA results in a significant decrease of GSC sphere-forming ability and self-renewal capacity. Inhibition of TGF-β signaling leads to Sox2 downregulation, depriving GSC of stemness, promoting GSC differentiation, and reducing their tumorigenicity in orthotopic immune compromised mice. There are also other GSC-related signaling pathways in which TGF-β is involved. Penuelas et al. demonstrated that TGF-β increases GSC self-renewal capacity through the Smad-dependent induction of leukemia inhibitory factor (LIF) and the subsequent activation of the JAK-STAT signaling pathway (Figure 1) [58]. Furthermore, GB neurospheres that are pretreated with TGF-β or LIF generate tumors earlier and decrease survival significantly in mice compared with untreated GB neurospheres [58].

A GSC-enriched cell population has been found to express high levels of CD44 and inhibitor of DNA-binding protein1 (Id1) and tend to be located in a perivascular niche [59], a place suitable for GSC expansion and tumor development [60]. High CD44 and Id1 levels correlate with poor prognosis in GB patients [59]. Inhibition of the TGF-β signaling cascade by blockade of TGFβRI decreases the CD44<sup>high</sup>/Id1<sup>high</sup> GSC population through reduction of Id1 and Id3 transcription factors levels, resulting in an inhibition of their ability to initiate tumors (Figure 1) [59].

GSC not only often locate in perivascular niches, but also generate vascular pericytes to promote vessel function and tumor growth [61]. CXCR4-expressing GSC are recruited toward endothelial cells in brain and GB through SDF-1/CXCR4 axis, and are induced to become pericytes mainly by TGF-β [61].

**Preclinical and clinical studies on TGF-β inhibition in glioma**

Therapeutic inhibition of TGF-β signaling can be accomplished by inhibiting translation of TGF-β mRNA using antisense oligonucleotides (AON), sequestering the ligands using soluble receptors or their ectodomain constructs (ligand
TGF-β signaling and its targeting for glioma treatment

Table 1. Anti-TGF-β compounds currently under clinical development for glioma treatment (summarized from www.clinicaltrials.gov)

<table>
<thead>
<tr>
<th>Drug</th>
<th>Type</th>
<th>Target</th>
<th>Clinical trial identifier and status</th>
</tr>
</thead>
<tbody>
<tr>
<td>AP12009</td>
<td>AON</td>
<td>TGF-β2</td>
<td>NCT00431561, Phase IIb completed [65]</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td>NCT00761280, Phase III terminated</td>
</tr>
<tr>
<td>LY2157299</td>
<td>Kinase inhibitor</td>
<td>TGFβR1 (ALK-5)</td>
<td>NCT01682187, Phase I recruiting [71, 72]</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td>NCT01220271, Phase I/II recruiting</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td>NCT01582269, Phase II recruiting</td>
</tr>
<tr>
<td>GC1008</td>
<td>Antibodies</td>
<td>TGF-β</td>
<td>NCT01472731, Phase II completed [74]</td>
</tr>
</tbody>
</table>

traps) and antibodies, and suppressing TGF-β receptor kinase activity (Figure 1) [62]. Below, we show a summary of pre-clinical studies and clinical trials exploring TGF-β inhibition as a therapeutic approach in glioma. Several therapeutic approaches explored to inhibit oncopigenic TGF-β signaling involved in glioma, which are documented in the clinical study database (www.clinicaltrials.gov), are summarized in Table 1.

Antisense TGF-β oligonucleotides

The most effective AON so far for high-grade glioma therapy is a phosphorothioate-modified AON, AP12009 (trabedersen), which is complementary to the human TGF-β2 mRNA sequence (Figure 1, Table 1). Based on three early-passage primary tumor cell cultures isolated from high-grade glioma patients, AP12009 treatment significantly reduced TGF-β2 protein secretion by 49% to 73% compared to untreated and nonsense controls [63]. AP12009 also reduces glioma cell proliferation and migration and reverses the immunosuppressive effects resulted from TGF-β2 [64]. In a phase IIb study, AP12009 was infused intratumorally by a convection-enhanced delivery, which bypassed the blood-brain-barrier and achieved a homogeneous distribution throughout the tumor. In anaplastic astrocytoma (AA, grade III glioma) patients, the median survivals were 39.1 months in the 10 µM AP12009 arm (n = 12) and 35.2 months in the 80 µM AP12009 arm (n = 15), compared with 21.7 months in the chemotherapy arm (n = 12). In this study with limited numbers of patients, AP12009 shows the trend of treatment benefits, but the trend is not statistically significant. However, the benefit was not observed in the patients with GB [65]. In addition, the frequency of glioma patients (with AA or GB) experiencing adverse events was higher with standard chemotherapy (64%) than with 10 or 80 µM AP12009 (27% and 43%, respectively) [65]. Information from the clinical study database (Table 1) indicated that a phase III clinical trial with AP12009 has been temporarily terminated due to insufficient number of suitable participants recruited within the planned period.

Modulation of TGF-β receptors

Soluble receptors can bind to TGF-β, thereby preventing it from binding to its cell surface receptors (Figure 1) [66]. Naumann et al. used adenoviral gene transfer to express secreted TGFβRII in the human glioma cell line LN-229, leading to reduced Smad2 phosphorylation and enhanced NK cell cytotoxicity against glioma cells. LN-308 glioma cells expressing the secreted TGFβRII had significantly delayed growth compared to control cells in an intracebral xenograft nude mouse model [66]. Another therapeutic method to inhibit TGF-β signaling is to block TGFβRI or TGFβRII kinase activity, thereby preventing phosphorylation of downstream effectors such as R-Smads. SB-431542 is a novel, small molecule kinase inhibitor of type I TGF-β receptor (Figure 1) [67]. It is not surprising that SB-431542 treatment results in blockade of Smad phosphorylation and nuclear translocation, and inhibition of expression of TGF-β downstream targets, VEGF and PAI-1. Consequently, SB-431542 treatment inhibits in vitro glioma proliferation and migration [67]. LY2109761, a novel TGF-β receptor type I and type II dual inhibitor (Figure 1), has been shown to inhibit tumor development in a variety of murine tumor models including pancreatic cancer and hepatocellular carcinoma [68, 69]. LY2109761 reduces in vitro survival of U87 and T98 glioma cell lines along with an anti-migratory and anti-angiogenic effects. Using a subcutaneous xenograft U87 or T98 model, LY2109761 impedes tumor growth alone or in combination with radiation and temozolomide (TMZ). LY2109761 also
decreases tumor blood perfusion as measured by noninvasive dynamic contrast-enhanced magnetic resonance imaging [70].

In a phase 1 dose-escalation study regarding TGFβRI inhibitor LY2157299 monohydrate (Figure 1, Table 1), 16.6% (5/30) and 7.7% (2/26) of patients with glioma had either a complete response (CR) or a partial response (PR) in the LY2157299 monotherapy arm and the LY2157299-lomustine combination arm, respectively [71, 72]. In both groups, 15 patients with glioma had stable disease (SD), among whom 5 had SD ≥ 6 cycles of treatment. In total, 12/56 (21.4%) of glioma patients had a clinical benefit (CR, PR, or SD ≥ 6 cycles), which correlated with low expression of pSmad2 (normalized to total Smad2) in their tumors. LY2157299 was safe on intermittent administration (14 days on/14 days off) of 300 mg/day for 28 days without cardiac adverse effects [71, 72].

Antibodies

The pan-TGF-β neutralizing antibody 1D11 (Figure 1) enters both subcutaneous and intracranial implanted gliomas after intravenous injection and remains detectable within the tumor for several days, while only minimal amounts of 1D11 are found in other organs and tissues [73]. However, 1D11 shows different effects on the treatment of gliomas in immunocompetent and immunodeficient mice [73]. Treatment of immunocompetent mice bearing subcutaneous GL261 tumors with 1D11 results in complete remission, but for unknown reasons, repetition of the treatment in immune deficient mice with subcutaneous GL261 tumors shows an opposite effect [73]. In addition, while intracranially implanted GL261 glioma cells in immunocompetent C57BL/6J mice show no tumor reduction after the 1D11 treatment, the glioma cells show less invasion into the adjacent areas of the brain [73]. A Phase II study of the human analog of the 1D11 antibody, GC1008 (Figure 1, Table 1), for the treatment of glioma has been completed [74]. FZr-GC1008 showed excellent and specific uptake by recurrent gliomas, determined by positron emission tomography (PET) scan. No major toxicity was observed in GC1008 treatment, but all patients showed clinical and/or radiological disease progression after 1 to 3 rounds of the treatment. Thus, in this study with 12 patients, clinical benefit of GC1008 was not achieved [74].

Concluding remarks

Gliomas are characterized by aggressive proliferation, diffuse infiltration and resistance to radio- and chemotherapy. As TGF-β plays a major role in glioma progression, targeting of TGF-β or its downstream signaling in combination with radio-chemotherapy might be a promising therapeutic approach. Inhibitors of the TGF-β pathway developed so far comprise several classes, as listed above. Some of these classes have entered clinical trials for the treatment of glioma as well as other types of cancer. Although various studies have demonstrated the potential benefits of targeting the TGF-β signaling pathway in glioma, data are not consistently encouraging. The reason could be that inhibition of either the TGF-β receptor binding or kinase activity may also result in alternative compensatory pathways mediated by other activators of the Smad pathway or Smad independent factors [2]. Thus, in addition to targeting the TGF-β signaling pathway alone, a synergistic response may be achieved by simultaneously targeting other aberrant signaling pathways such as EGFR, PI3K/Akt, NF-κB, JAK/STAT, etc. Indeed, in preclinical studies in pancreatic tumors, targeting the EGFR and TGF-β signaling pathways concurrently shows better efficacy than targeting either signaling pathway alone [75]. Several clinical trials evaluating the effects of the TGFβRI kinase inhibitor LY-2157299 in combination with Sorafenib (a small molecular inhibitor of multiple tyrosine protein kinases and Raf kinases) in hepatocellular carcinoma are also ongoing (NCT02240433, NCT02178358, NCT01246986). Importantly, the combination of TGF-β signaling inhibitors with U.S. FDA-approved immune checkpoint blockade agents, such as anti-PD1, anti-PD-L1, and anti-CTLA4 antibodies, most likely would improve clinical outcomes over targeting a single pathway, especially as these antibodies have recently been shown to have efficacy in murine models of glioma [76-78].

Acknowledgements

This review was supported by the grant CA155521 from the National Institutes of Health. The authors sincerely thank David M. Lucas for his careful and critical reading of this manuscript.
TGF-β signaling and its targeting for glioma treatment

Disclosure of conflict of interest

The authors confirm that this article content has no conflicts of interest.

Address correspondence to: Jianhua Yu, Division of Hematology, Department of Internal Medicine, The Ohio State University, Biomedical Research Tower 816, 460 West 12th Avenue, Columbus, OH 43210, USA; Tel: 614-293-1471; Fax: 614-688-4028; E-mail: jianhua.yu@osumc.edu

References


[23] Maxwell M, Galanopoulos T, Neville-Golden J and Antoniades HN. Effect of the expression of


TGF-β signaling and its targeting for glioma treatment


TGF-β signaling and its targeting for glioma treatment

12009 in recurrent malignant gliomas: from preclinical to phase I/II studies. Oligonucleotides 2007; 17: 201-212.


